DFS
60
4
PDCO
41
3
UNH
55
5
OMC
62
3
DGX
36
3
EMC
71
9
ECL
57
3
DOV
61
4
AIV
51
4
HIG
54
2
GS
63
11
SYY
45
2
ETN
69
2
VZ
37
3
EQIX
60
3
GD
44
2
ROK
42
4
PM
66
6
CME
56
3
BRK.B
27
2
DFS
60
4
PDCO
41
3
UNH
55
5
OMC
62
3
DGX
36
3
EMC
71
9
ECL
57
3
DOV
61
4
AIV
51
4
HIG
54
2
GS
63
11
SYY
45
2
ETN
69
2
VZ
37
3
EQIX
60
3
GD
44
2
ROK
42
4
PM
66
6
CME
56
3
BRK.B
27
2
Financhill
Back

Janux Therapeutics 10K Form

Buy
57

JANX
Janux Therapeutics

Last Price:
54.80
Seasonality Move:
13.55%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive JANX News And Ratings

See the #1 stock for the next 7 days that we like better than JANX

JANX Financial Statistics

Sales & Book Value

Annual Sales: $8.08M
Cash Flow: $-10.12M
Price / Cash Flow: 0
Annual Sales: $12.61
Price / Book: 4.38

Profitability

EPS (TTM): -0.90000
Net Income (TTM): $-44.05M
Gross Margin: --
Return on Equity: -9.55%
Return on Assets: -8.85%

Janux Therapeutics Earnings Forecast

Key Janux Therapeutics Financial Ratios

  • The Research & Development expenses have been 679.48% of Revenue.
  • The Interest Expense is 0.00% of Operating Income.
  • The Net Earning history of JANX is -721.18% of Total Revenues.
  • Per Share Earnings over the last 5 years have been positive in 2 years.

Janux Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: JANX
Website: januxrx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 57.34
Quick Ratio: 57.02

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

JANX Technical Analysis vs Fundamental Analysis

Buy
57
Janux Therapeutics (JANX) is a Buy

Is Janux Therapeutics a Buy or a Sell?